title: Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma.
authors.forename: Thomas
authors.initials: T
authors.lastname: Lund
authors.forename: Niels
authors.initials: N
authors.lastname: Abildgaard
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Delaisse
authors.forename: Torben
authors.initials: T
authors.lastname: Plesner
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption / Q000517:prevention & control*; D004164:Diphosphonates / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications*; D012189:Retrospective Studies; D000077211:Zoledronic Acid
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid